股市必读：开立医疗一季报 - 第一季度单季净利润同比减91.94%

Core Points - The stock price of Kaili Medical (300633) closed at 30.31 yuan on April 25, 2025, down by 1.59% with a turnover rate of 0.79% and a trading volume of 34,200 shares, amounting to a transaction value of 104 million yuan [1] Group 1: Trading Information - On April 25, 2025, the capital flow for Kaili Medical showed a net outflow of 6.8552 million yuan from institutional investors and a net outflow of 2.5979 million yuan from speculative investors, while retail investors had a net inflow of 9.453 million yuan [2][8] Group 2: Shareholder Changes - As of March 31, 2025, the number of shareholders for Kaili Medical increased to 14,500, representing a growth of 736 shareholders or 5.34% compared to December 31, 2024. The average number of shares held per shareholder decreased from 31,400 shares to 29,800 shares, with an average market value of 867,600 yuan per shareholder [3][8] Group 3: Performance Disclosure - In the first quarter of 2025, Kaili Medical reported a main revenue of 430 million yuan, a year-on-year decrease of 10.29%. The net profit attributable to shareholders was 8.0746 million yuan, down by 91.94% year-on-year, while the net profit excluding non-recurring items was 5.9981 million yuan, a decline of 93.49% year-on-year. The company's debt ratio stood at 21.81%, with investment income of 979,200 yuan and financial expenses of -17.806 million yuan, resulting in a gross margin of 63.19% [4][8] Group 4: Management Responses - In response to investor inquiries regarding the impact of the US-China tariff conflict on the intravascular ultrasound (IVUS) business, the company noted that some foreign competitors are not affected by tariffs due to their products not originating from the US. The company emphasized its advantages in specialization and experience in ultrasound technology, which positions it well to capture market share in the IVUS segment over the next 3-5 years [5] - Regarding the higher gross margin in the domestic market compared to the international market for 2023-2024, the company attributed this to a higher proportion of high-end product models in its domestic revenue from ultrasound and endoscopy [6]